Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
ARCT Arcturus Therapeutics
13.620
-0.400-2.85%
Post Mkt Price
13.6200.0000.00%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Receivable Turnover(T)
427.9% 18.3982 31.23% 5.4321 1.54% 4.5007 1.54% 4.5007
Fixed Assets Turnover(T)
54.13% 1.5257 36.82% 1.3521 4.87% 1.2471 4.87% 1.2471
Total Asset Rate(T)
255.33% 0.1032 15.34% 0.0376 -16.74% 0.0284 -16.74% 0.0284
ROIC
23.51% -50.808% -13.06% -58.185% -82.38% -56.461% -82.38% -56.461%
ROE
14.97% -69.476% -15% -73.879% -90.84% -65.200% -90.84% -65.200%
ROA
22.66% -42.116% -12.4% -48.211% -81.41% -46.861% -81.41% -46.861%
Efficiency Ratios
ROE 5 Year Average
-- -- -- -- -7.03% -69.989% -- --
ROA 5 Year Average
-- -- -- -- -4% -36.033% -- --
Average 5 Years ROIC
-- -- -- -- -5.69% -50.423% -- --
Profitability Ratios TTM
Operating Margin
78.49% -404.097% 4.8% -1263.666% -118.9% -1641.330% -118.9% -1641.330%
Net Margin
78.24% -407.905% 2.55% -1282.612% -117.89% -1647.981% -117.89% -1647.981%
EBITDA Margin
78.4% -3.9799% 2.75% -12.5705% -118.95% -16.1669% -118.95% -16.1669%
R & D Expense Ratio
-74.91% 397.140% -1.71% 1089.450% 131.84% 1405.940% 131.84% 1405.940%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-72.95% 106.950% -14.02% 274.220% 37.8% 335.390% 37.8% 335.390%
Financial Health Ratios
Long-Term Debt to Equity Ratio
97.32% 39.811% 29.39% 23.433% 338.89% 19.778% 338.89% 19.778%
Total Assets to Common Equity
34.44% 197.411% 35.57% 185.110% 43.26% 172.128% 43.26% 172.128%
Debt to Asset Ratio
158.7% 57.639% 93.03% 37.459% 479.05% 30.299% 479.05% 30.299%
Current Ratio
-49.22% 3.1431 -65.42% 3.0474 -59.7% 3.8072 -59.7% 3.8072
Quick Ratio
-49.96% 3.081 -65.72% 3.0135 -60% 3.756 -60% 3.756
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- 20.71% -7.770% -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. It is a clinical-stage mRNA medicines and vaccines company, which focuses on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The firm's products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
CEO: Mr. Joseph E. Payne
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...